EMA Authorised: Lojuxta (Lomitapide) — Chiesi Farmaceutici SpA

View source ↗

Summary

The EMA authorised Lojuxta (lomitapide) for the treatment of hypercholesterolemia, with Chiesi Farmaceutici SpA as the marketing authorisation holder; decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• Lojuxta (lomitapide)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia. MAH: Chiesi Farmaceutici SpA. Decision date: 27/01/2025